Intranasal
Preclinical only
435 nmol intranasal orexin-A
Context: small narcolepsy study
Route safety: Non-human or laboratory exposure. It cannot be converted into a human dose.
Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: Orexin-A evidence and protocol review
Also known as: Hypocretin-1
Orexin-A (hypocretin-1) is a hypothalamic neuropeptide central to wakefulness, arousal, and appetite/energy-homeostasis regulation, acting via orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). Structure-activity relationship studies of orexin A and orexin B at both human orexin receptors have produced receptor-selective ligands, including orexin A(2-33), identified as the first analog with OX1R receptor preference - research that has informed the broader development of orexin-receptor-targeted compounds (including FDA-approved orexin-receptor antagonists for insomnia, a distinct drug class from orexin-A itself).
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
435 nmol intranasal orexin-A
Context: small narcolepsy study
Route safety: Non-human or laboratory exposure. It cannot be converted into a human dose.
No route-specific amount established in the reviewed record.
Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
This was a small experimental study, not an approved product or general wakefulness protocol. Peptide delivery and identity are formulation-critical.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.